Syndax Pharmaceuticals Inc (22)
Browse by Contract Category
Contracts
-
Underwriting Agreement, dated December 8, 2020, by and among the Company, Goldman Sachs & Co. LLC, Citigroup Global Markets Inc. and Cowen and Company, LLC
(Filed With SEC on December 9, 2020)
-
Executive Employment Agreement by and between the Company and Daphne Karydas, dated as of July 6, 2020
(Filed With SEC on November 5, 2020)
-
Amendment No. 12 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated May 12, 2020
(Filed With SEC on August 6, 2020)
-
Amendment No. 1 to License Agreement by and between the Company and UCB Biopharma Sprl, dated as of July 9, 2019
(Filed With SEC on November 7, 2019)
-
Form of Stock Unit Agreement under 2015 Omnibus Incentive Plan
(Filed With SEC on August 6, 2020)
-
Loan and Security Agreement dated February 7, 2020 between Syndax Pharmaceuticals, Inc. and Hercules Capital, Inc
(Filed With SEC on May 7, 2020)
-
Amended and Restated Executive Employment Agreement by and between the Company and Richard P. Shea, dated as of April 27, 2020
(Filed With SEC on May 7, 2020)
-
Amended and Restated Executive Employment Agreement by and between the Company and Michael L. Meyers, M.D., Ph.D., dated as of April 27, 2020
(Filed With SEC on May 7, 2020)
-
Amended and Restated Executive Employment Agreement by and between the Company and Michael A. Metzger, dated as of April 27, 2020
(Filed With SEC on May 7, 2020)
-
Amended and Restated Executive Employment Agreement by and between the Company and Briggs W. Morrison, M.D., dated as of April 27, 2020
(Filed With SEC on May 7, 2020)
-
Non-employee Director Compensation Policy, as amended, February 12, 2020
(Filed With SEC on May 7, 2020)
-
Underwriting Agreement, dated April 30, 2020, by and among the Company, Citigroup Global Markets Inc. and Cowen and Company, LLC
(Filed With SEC on May 4, 2020)
-
Description of Capital Stock
(Filed With SEC on March 5, 2020)
-
Purchase Agreement between the Company and the Purchasers, dated January 30, 2020
(Filed With SEC on February 4, 2020)
-
Form of Pre-Funded Warrant
(Filed With SEC on February 4, 2020)
-
Amendment No. 11 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated July 1, 2019
(Filed With SEC on November 7, 2019)
-
Amendment No. 1 to License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of January 25, 2019
(Filed With SEC on May 8, 2019)
-
Form of Series Warrant
(Filed With SEC on March 29, 2019)
-
Purchase Agreement between the Company and the Purchaser, dated March 28, 2019
(Filed With SEC on March 29, 2019)
-
Purchase Agreement between the Company and the Purchasers, dated March 26, 2019
(Filed With SEC on March 29, 2019)
-
Form of Pre-Funded Warrant
(Filed With SEC on March 29, 2019)
-
Amendment No. 10 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated October 15, 2018
(Filed With SEC on March 7, 2019)